2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
27
Lung Neoplasms
7
Neoplasm Metastasis
4
Recurrence
3
Non Small Cell Lung Cancer Metastatic
3
Neuroblastoma
3
Neoplasms
3
Meningeal Carcinomatosis
2
Brain Neoplasms
2
Advanced Non-Small Cell Lung Cancer
2
ALK Positive Non-small Cell Lung Cancer
2
Thrombocytosis
1
Sexual Dysfunction, Physiological
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Non-Small Cell Lung Cancer ALK-positive
1
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
1
Neurofibromatosis 1
1
Neoadjuvant Non-Small Cell Lung Cancer
1
NSCLC
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Diseases
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
Carboplatin
19
Pemetrexed
10
Paclitaxel
7
pembrolizumab
5
Nivolumab
5
Cisplatin
5
Gemcitabine
4
osimertinib
3
entinostat
3
camrelizumab
3
atezolizumab
3
Erlotinib Hydrochloride
3
Bronchoscopy
3
zipalertinib
2
selpercatinib
2
pralsetinib
2
durvalumab
2
apatinib
2
Vinorelbine
2
Surveys and Questionnaires
2
One-Lung Ventilation
2
Ipilimumab
2
Drug Delivery Systems
2
Docetaxel
2
Blood Specimen Collection
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
zimberelimab
1
toripalimab
1
taletrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Diseases
×
lorlatinib
×
Clear all
NCT05167500
2023-03-30
LORLAPULM
Fundación GECP
Completed
118 enrolled